
Eli Lilly’s GLP-1 analogue, Dulaglutide, is better at controlling blood sugar levels than three other major diabetes products. At least that is what clinical data from three phase III trials, published by the American pharma group the past weekend at the world’s largest diabetes congress held by the American Diabetes Association, indicate.
The three diabetes drugs in question are generic drug metformin, Byetta (exenatide) from Bristol-Myers Squibb, and Merck’s blockbuster Januvia (sitagliptin). The three trials also show that diabetes patients shed twice as many kilos by using Dulaglutide instead of Januvia.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app